Emerging strategies in the initial management of locally advanced rectal cancer.

Biomarkers, Tumor / blood Chemoradiotherapy / methods Circulating Tumor DNA / blood Combined Modality Therapy Humans Neoadjuvant Therapy Neoplasm Recurrence, Local / drug therapy Oxaliplatin / therapeutic use Quality of Life Radiotherapy, Adjuvant / methods Rectal Neoplasms / blood Sequence Analysis, DNA
neoadjuvant therapy rectal cancer sequencing

Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
Sep 2019
Historique:
pubmed: 20 8 2019
medline: 30 1 2020
entrez: 20 8 2019
Statut: ppublish

Résumé

The initial management of locally advanced rectal cancer continues to evolve and formulating the ideal treatment plan remains challenging, with a multitude of emerging treatment strategies and either limited or inconsistent data to support these. The main objective of neoadjuvant treatment is to maximize disease control and minimize toxicity and impact on quality of life. Ultimately, the optimal approach needs to be personalized to the individual. In this Review, we discuss the various strategies currently used and being further investigated in the initial treatment of patients presenting with locally advanced rectal cancer. We describe the evidence behind the current standard of care recommendations and emerging new options, as well as potential biomarkers that may assist with further refining treatment selection.

Identifiants

DOI: 10.2217/fon-2018-0941 PMID: 31424262
pubmed: 31424262
doi: 10.2217/fon-2018-0941
doi:

Substances chimiques

Biomarkers, Tumor 0
Circulating Tumor DNA 0
Oxaliplatin 04ZR38536J

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2955-2965

Auteurs

Lucy Gately (L)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.

Hui-Li Wong (HL)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.

Jeanne Tie (J)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
Department of Medical Oncology, Western Health Medical School, University of Melbourne, Footscray, Victoria, Australia.

Rachel Wong (R)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia.
Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.

Margaret Lee (M)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, Western Health Medical School, University of Melbourne, Footscray, Victoria, Australia.
Department of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia.

Belinda Lee (B)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
Department of Medical Oncology, Northern Health, Epping, Victoria, Australia.

Azim Jalali (A)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.

Peter Gibbs (P)

Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, Western Health Medical School, University of Melbourne, Footscray, Victoria, Australia.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Emerging strategies in the initial management...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Chimioradiothérapie › Emerging strategies in the initial management...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › ADN tumoral › ADN tumoral circulant › Emerging strategies in the initial management...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Emerging strategies in the initial management...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Emerging strategies in the initial management...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Traitement néoadjuvant › Emerging strategies in the initial management...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Emerging strategies in the initial management...
questionsmedicales.fr › Composés chimiques organiques › Complexes de coordination › Oxaliplatine › Emerging strategies in the initial management...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Emerging strategies in the initial management...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Radiothérapie adjuvante › Emerging strategies in the initial management...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Tumeurs du rectum › Emerging strategies in the initial management...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Emerging strategies in the initial management...